Cleared Traditional

K770520 - RADIOIMMUNOASSAY

K770520 is the FDA 510(k) clearance for RADIOIMMUNOASSAY by Kallestad Laboratories, Inc.. It is a Class 2 Chemistry device (product code CDP) cleared through the Traditional 510(k) pathway after a 77-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jun 1977
Decision
77d
Days
Class 2
Risk

K770520 is an FDA 510(k) clearance for the RADIOIMMUNOASSAY, QUANTITIPE 125-I-T3. Classified as Radioimmunoassay, Total Triiodothyronine (product code CDP), Class II - Special Controls.

Submitted by Kallestad Laboratories, Inc. (Mchenry, US). The FDA issued a Cleared decision on June 3, 1977 after a review of 77 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1710 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Kallestad Laboratories, Inc. devices

Submission Details

510(k) Number K770520 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 18, 1977
Decision Date June 03, 1977
Days to Decision 77 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
11d faster than avg
Panel avg: 88d · This submission: 77d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code CDP Radioimmunoassay, Total Triiodothyronine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1710
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - CDP Radioimmunoassay, Total Triiodothyronine

All 93
Devices cleared under the same product code (CDP) and FDA review panel - the closest regulatory comparables to K770520.
REAGENT, T-3 UPTAKE
K770738 · G.D. Searle and Co. · Jun 1977
SERUM SET, THYROID CONTROL
K770739 · G.D. Searle and Co. · Jun 1977
QUANTIMUNE T-3 RIA
K770648 · Bio-Rad · Jun 1977
T-3 RIA REAGENT SET
K770677 · G.D. Searle and Co. · May 1977
T3 RIA (PEG) DIAGNOSTIC KIT
K770201 · Abbott Laboratories · Apr 1977
CENTRIA T3 RIA
K761305 · Union Carbide Corp. · Dec 1976